American Century Companies
AXSM icon

American Century Companies’s Axsome Therapeutics AXSM Stock Holding History

American Century Companies’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-6,658
Closed -$777K – 2859
2025
Q1 		$777K Sell
6,658
-73
-1% -$8.32K ﹤0.01% 2343
2024
Q4 		$570K Buy
+6,731
New +$619K ﹤0.01% 2456
2023
Q3 		– Sell
-3,893
Closed -$280K – 2852
2023
Q2 		$280K Buy
+3,893
New +$287K ﹤0.01% 2416
2021
Q3 		– Sell
-129,303
Closed -$8.72M – 2288
2021
Q2 		$8.72M Buy
129,303
+492
+0.4% +$29.5K 0.01% 858
2021
Q1 		$7.29M Sell
128,811
-2,572
-2% -$181K 0.01% 844
2020
Q4 		$10.7M Buy
131,383
+14,694
+13% +$1.1M 0.01% 749
2020
Q3 		$8.31M Buy
116,689
+40,349
+53% +$3.14M 0.01% 744
2020
Q2 		$6.28M Buy
+76,340
New +$5.88M 0.01% 749

Other funds holding AXSM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

American Century Companies's AXSM Position: Q2 2025 in Review

American Century Companies sold out of Axsome Therapeutics (AXSM) in Q2 2025, closing a stake of 6,658 shares — an estimated $777K sold.

American Century Companies first reported a position in AXSM in Q2 2020 and held it in 8 quarters. The position peaked at $10.7M in Q4 2020. 348 funds tracked by Wall St. Rank hold AXSM as of Q2 2025.

  • American Century Companies reported no remaining Axsome Therapeutics position as of Q2 2025 after selling out during the quarter.
  • American Century Companies sold 6,658 Axsome Therapeutics shares in Q2 2025, an estimated $777K.
  • American Century Companies first reported a position in Axsome Therapeutics in Q2 2020 and held it in 8 quarters.
  • American Century Companies's Axsome Therapeutics position peaked at $10.7M in Q4 2020.
  • 348 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2025.

Based on American Century Companies's 13F filing for Q2 2025, filed 12 Aug 2025.